Chimerix (CMRX) Expected to Announce Quarterly Earnings on Thursday

Chimerix (NASDAQ:CMRX) will likely be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Chimerix to post earnings of ($0.26) per share and revenue of $0.31 million for the quarter.

Chimerix Price Performance

Chimerix stock opened at $4.96 on Wednesday. The firm has a market cap of $446.08 million, a price-to-earnings ratio of -5.28 and a beta of 0.32. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $5.53. The firm has a fifty day moving average price of $4.00 and a two-hundred day moving average price of $2.14.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CMRX. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Tuesday, February 18th. Wedbush reiterated an “outperform” rating and set a $7.00 target price (up from $6.00) on shares of Chimerix in a research note on Tuesday, February 18th.

Insider Transactions at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is owned by corporate insiders.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.